ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone353-1291-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.60 billion
Profitability
Miscellaneous
Employees13,670
Next Earnings Date10/23/2019 (Estimated)
OptionableOptionable
Icon (NASDAQ:ICLR) Frequently Asked Questions
What is Icon's stock symbol?
Icon trades on the NASDAQ under the ticker symbol "ICLR."
How were Icon's earnings last quarter?
Icon Plc (NASDAQ:ICLR) posted its quarterly earnings results on Wednesday, July, 24th. The medical research company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.68 by $0.01. The medical research company had revenue of $695.14 million for the quarter, compared to analyst estimates of $693.56 million. Icon had a return on equity of 25.02% and a net margin of 13.05%. The company's quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.51 EPS. View Icon's Earnings History.
When is Icon's next earnings date?
What guidance has Icon issued on next quarter's earnings?
Icon issued an update on its FY19 earnings guidance on Wednesday, July, 24th. The company provided earnings per share (EPS) guidance of $6.75-6.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.88. The company issued revenue guidance of $2.76-2.84 billion, compared to the consensus revenue estimate of $2.81 billion.
What price target have analysts set for ICLR?
8 equities research analysts have issued 1 year price objectives for Icon's stock. Their forecasts range from $154.00 to $171.00. On average, they anticipate Icon's share price to reach $164.8333 in the next twelve months. This suggests a possible upside of 6.6% from the stock's current price. View Analyst Price Targets for Icon.
What is the consensus analysts' recommendation for Icon?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.
Has Icon been receiving favorable news coverage?
News coverage about ICLR stock has been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Icon earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Icon.
Are investors shorting Icon?
Icon saw a increase in short interest in the month of August. As of August 15th, there was short interest totalling 498,700 shares, an increase of 12.1% from the July 15th total of 444,800 shares. Based on an average daily volume of 252,500 shares, the short-interest ratio is presently 2.0 days. Approximately 0.9% of the company's stock are sold short. View Icon's Current Options Chain.
Who are some of Icon's key competitors?
Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).
What other stocks do shareholders of Icon own?
Who are Icon's key executives?
Icon's management team includes the folowing people:
- Dr. Steven A. Cutler, CEO & Director (Age 59)
- Mr. Brendan Brennan, Chief Financial Officer (Age 40)
- Jonathan Curtain, VP of Corp. Fin. & Investor Relations
- Mr. Thomas O'Leary, Chief Information Officer
- Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)
Who are Icon's major shareholders?
Icon's stock is owned by many different of retail and institutional investors. Top institutional investors include WCM Investment Management LLC (6.28%), Renaissance Technologies LLC (4.20%), Acadian Asset Management LLC (3.98%), Earnest Partners LLC (3.90%), Wasatch Advisors Inc. (2.82%) and Boston Partners (2.71%).
Which major investors are selling Icon stock?
ICLR stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Point72 Asset Management L.P., Grantham Mayo Van Otterloo & Co. LLC, Morgan Stanley, Ellis Investment Partners LLC, Boston Partners, Earnest Partners LLC and Foresters Investment Management Company Inc..
Which major investors are buying Icon stock?
ICLR stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Comgest Global Investors S.A.S., Bank of New York Mellon Corp, Wasatch Advisors Inc., Legato Capital Management LLC, WCM Investment Management LLC, Marshall Wace LLP and Marshall Wace North America L.P..
How do I buy shares of Icon?
Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Icon's stock price today?
One share of ICLR stock can currently be purchased for approximately $154.62.
How big of a company is Icon?
Icon has a market capitalization of $8.34 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.
What is Icon's official website?
How can I contact Icon?
Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.
MarketBeat Community Rating for Icon (NASDAQ ICLR)
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
